Alba Therapeutics Corp. Of Baltimore Begins Phase I Trial of Its Celiac Disease Treatment
Posted on: Wednesday, 28 September 2005, 21:00 CDT
By Daily Record Staff and Wire Reports
Alba Therapeutics Corp., of Baltimore, announced that it has begun a Phase I trial of AT-1001, an orally administered drug that is being developed for the treatment of Celiac Disease, a digestive disease, and other autoimmune diseases
. Individuals with Celiac Disease are unable to digest gluten, a mixture of proteins found in common food grains such as wheat, rye and barley.Source: The Daily Record (Baltimore)
Related Articles
- Microbiology Profile in Women With Pelvic Inflammatory Disease in Relation to IUD Use
- Pelvic Inflammatory Disease During the Post-Partum Year
- A Chlorotic Spot Disease on Calla Lilies (Zantedeschia Spp.) Is Caused By a Tospovirus Serologically but Distantly Related to Watermelon Silver Mottle Virus
- Disease Notes: March 3, 2005
- A New Link to Parkinson's Disease
- Artist's Skills Blossom After Brain Disease
- Alcohol Doesn't Protect Against Parkinson's Disease
- Beating Odds of Heart Disease, Stroke in Diabetics
- Alzheimer's Disease
- Addison's Disease
Rating: 2.5 / 5 (8 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds